Document is current
Any future updates will be listed below
-
Authors
Corti, Chiara http://orcid.org/0000-0002-0359-0267
Giugliano, Federica http://orcid.org/0000-0003-3856-5528
Nicolò, Eleonora http://orcid.org/0000-0001-5042-6550
Tarantino, Paolo http://orcid.org/0000-0001-8686-0228
Criscitiello, Carmen http://orcid.org/0000-0001-9064-0113
Curigliano, Giuseppe http://orcid.org/0000-0003-1781-2518
- License Information
-
More Information
Article History
Accepted: 15 February 2023
First Online: 27 March 2023
Compliance with Ethical Standards
:
: Chiara Corti, Federica Giugliano, and Eleonora Nicolò have no potential conflicts of interest to disclose. Paolo Tarantino reports honoraria from AstraZeneca. Carmen Criscitiello reports personal fees for consulting, advisory role, and speakers’ bureau from Lilly, Roche, Novartis, MSD, Seagen, Gilead, and Pfizer. All the competing interests were outside the submitted work. Giuseppe Curigliano reports the following honoraria for speaker’s engagement: Roche, Seattle Genetics, Novartis, Lilly, Pfizer, Foundation Medicine, NanoString, Samsung, Celltrion, BMS, MSD; honoraria for providing consultancy: Roche, Seattle Genetics, NanoString; honoraria for participating in Advisory Board: Roche, Lilly, Pfizer, Foundation Medicine, Samsung, Celltrion, Mylan; honoraria for writing engagement: Novartis, BMS; honoraria for participation in Ellipsis Scientific Affairs Group; institutional research funding for conducting phase I and II clinical trials: Pfizer, Roche, Novartis, Sanofi, Celgene, Servier, Orion, AstraZeneca, Seattle Genetics, AbbVie, Tesaro, BMS, Merck Serono, Merck Sharp Dome, Janssen-Cilag, Philogen, Bayer, Medivation, Medimmune. All the competing interests were outside the submitted work.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
